Thyroid Gland Carcinoma

P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P=N/A, N=600, Recruiting, Hospices Civils de Lyon

P=N/A, N=2, Completed, University of California, Los Angeles | Recruiting --> Completed | N=125 --> 2

These findings demonstrate that D3 sustains the tumorigenic potential of BCC CSCs by protecting them from TH-induced apoptosis and differentiation. Targeting the D3/TH axis may represent a promising therapeutic strategy to reduce the ability to self-renew of CSCs and inhibit tumor progression in BCC.

Its stability and independence from common confounders make it a valuable complement to calcitonin. The combined assessment of calcitonin and procalcitonin enhances diagnostic performance and should be considered in routine clinical practice.

P1, N=26, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jul 2026 --> Jun 2025

Emphasis is placed on standardization needs, verification of analytical performance, and the importance of consistent assay use in patient follow-up. Ultimately, the effective management of MTC biomarkers requires active engagement of clinical chemists and pathologists within multidisciplinary teams to ensure accurate interpretation, resolve analytical ambiguities, and integrate biochemical data into evidence-based therapeutic decision-making.

Measuring Tg and Tg antibody levels post-TL can provide a baseline for future reference. However, this case illustrates that high levels of Tg can be seen in the absence of thyroid cancer and therefore cannot reliably predict the risk of recurrence.

After four cycles of chemotherapy, the patient achieved partial regression of metastatic lesions. The highly aggressive nature of PRMS emphasizes the importance of having individualized and multidisciplinary treatment approaches to such rare cases.

Differentiated thyroid carcinoma in children is characterized by a number of clinical and molecular genetic features, which determines the need for a specialized multidisciplinary approach to their management. The high risk of malignancy in nodules, frequent regional dissemination and peculiarities of the molecular profile argue for the necessity of early diagnosis, integration of molecular testing and personalized choice of the volume of surgical intervention in the conditions of specialized centers.

In conclusion, when surgical near-total thyroidectomy is performed in patients with papillary thyroid carcinoma, a new malignancy may develop in the residual thyroid tissue even after many years. In such cases, completion total thyroidectomy and adjuvant multimodal treatment methods should be preferred.